PVLA ▲ +2.1% - Palvella Therapeutics, Inc.
$PVLA - Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set
28-OCT-2026 07:30 AM ET
Share this post
More filings for $PVLA
PVLA ▼ -0.2% - Palvella Therapeutics, Inc.Oct 15, 2026PVLA ▲ +0.0% - Palvella Therapeutics, Inc.Oct 13, 2026PVLA ▼ -0.1% - Palvella Therapeutics, Inc.Oct 12, 2026PVLA ▲ +0.5% - Palvella Therapeutics, Inc.Sep 9, 2026PVLA - Palvella Therapeutics, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026PVLA - Palvella Therapeutics, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026
View full $PVLA filing history →💬 Comments
Loading comments…
Leave a comment